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INTRODUCTION
The role of Neuropeptide FF (NPFF) and its analogs in pain modulation is ambiguous. Although "classically" NPFF is characterized as an anti-opioid peptide, it has been shown to also elicit robust antinociceptive effects depending on the dose and route of administration employed (for review see (Yang et al., 2008 either elicits antinociception or potentiates the antinociceptive effect of morphine (Kontinen and Kalso, 1995; Gouarderes et al., 1996; Xu et al., 1999) . In contrast, intracerebroventricular administration of these agents antagonizes morphine-induced antinociception (Gicquel et al., 1992; Oberling et al., 1993; Dupouy and Zajac, 1995) .
To date, two NPFF receptor subtypes, termed FF1 and FF2, have been identified and subsequently cloned (Bonini et al., 2000; Elshourbagy et al., 2000) . Presently, the specific role of each NPFF receptor subtype, with respect to pain modulation, has not been adequately described. The lack of selective pharmacological tools suitable for systemic administration has made elucidating the in vivo pharmacology of these receptors challenging. Based on results from ligand binding studies in rodents, it is clear that both NPFF receptors are widely expressed in brain tissue, whereas, only the FF2 receptor is expressed spinally (Bonini et al., 2000; Liu et al., 2001; Yang and Iadarola, 2006) . The lack of spinal FF1 receptors has led to the hypothesis that the antinociceptive actions of NPFF are mediated via FF2 receptors, whereas, the pronociceptive actions of NPFF are mediated via FF1 receptors (Liu et al., 2001) . We have identified several novel small
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-6-molecule, non-peptidic, ligands with varying degrees of functional selectivity for the NPFF receptor subtypes (Gaubert et al., 2009) . The goal of this investigation was to utilize these pharmacological tools in order to define the roles of the NPFF receptors as they pertain to pain modulation.
Here, we present the in vitro and in vivo profiles for a representative set of ligands that have allowed us to unmask the putative roles of the NPFF receptor subtypes. Based structures of these compounds have been disclosed elsewhere (Gaubert et al., 2009 JPET # 164384
-10-described previously (Mollereau et al., 2002 This article has not been copyedited and formatted. The final version may differ from this version. Table 1 ). As internal reference standards, the peptides NPAF and NPFF were used for FF1 and FF2 receptors, respectively. The pEC 50 values obtained for these reference peptides in the R-SAT and cAMP assays were consistent with those reported elsewhere using other functional assays (Kotani et al., 2001; Liu et al., 2001 ). In The selective FF2 agonist, AC-263093, retained its selectivity in the binding assay (~2 fold for FF2 over FF1), whereas, AC-262616 displayed equal or increased affinity for the FF1 receptor (Table 1) . Furthermore, AC-263093 showed little to no binding across a broad screening panel (n = 50) of other receptors, channels and enzymes (CEREP; IC 50 ≥ 10 μM).
In vitro characterization of non-peptidic small molecule FF1 antagonists. The in vitro
receptor profiles of several novel, non-peptidic, small molecule NPFF antagonists were determined using recombinant human FF1 and FF2 receptors. Two functional assay formats, including R-SAT and cAMP assays, as well as binding assays using [ 125 I]-NPFF were used for this characterization ( Figure 2 ; Table 2 ). As internal reference standards, the peptides BIBP-3226 and dPQR were included for comparison in both functional assays ( Table 2 ). The pK i values obtained for BIBP-3226 in the R-SAT and cAMP assays were consistent with those reported elsewhere (Mollereau et al., 2002) . The lack of stability of dPQR precluded us from characterizing it in R-SAT, however, the pK i value This article has not been copyedited and formatted. The final version may differ from this version. receptors with a pEC 50 value of 5.9 ± 0.5, representing a >150-fold lower activity at FF2
receptors based on functional activity in the R-SAT assay (Table 2) . The apparent lack of FF1 receptor expression spinally has led to the idea that the pronociceptive actions of NPFF are mediated via FF1 receptors (Liu et al., 2001 ).
However, this hypothesis has never been adequately addressed in vivo due to a lack of highly selective non-peptidic NPFF ligands suitable for systemic administration. Using our novel small molecule, non-peptidic, NPFF receptor ligands as pharmacological tools,
we have clearly demonstrated that NPFF receptors act in an opposing manner to modulate nociceptive input.
We were unable to detect any significant antinociceptive effects of AC-263093, a selective FF2 selective agonist, following IP administration in the hot plate test. While it remains plausible that NPFF agonists can potentiate the antinociceptive actions of opioids (Kontinen and Kalso, 1995; Gouarderes et al., 1996; Xu et al., 1999) , depending on the route of administration, this possibility was beyond the scope of the present investigation.
Given the lack of activity of AC-263093 on acute sensory thresholds, we also profiled this compound in the formalin and carrageenan models. Like morphine, AC-263093 markedly attenuated flinching behavior, although this effect was specific to the second phase, suggesting that AC-263093 may be active in models of spinal sensitization.
Consistent with this interpretation, AC-263093 dose-dependently alleviated thermal hyperalgesia produced by intraplantar carrageenan, an effect similar to that previously reported for 1DMe following intrathecal administration (Xu et al., 1999) . Increases in NPFF immunoreactivity have been reported in the spinal cord dorsal horn following carrageenan treatment (Kontinen et al., 1997) . Morphine pre-treatment completely blocks the increase in spinal NPFF immunoreactivity (Kontinen et al., 1997) , suggesting that agonists as well as provide a mechanism by which the antinociceptive activity of intrathecal morphine may be enhanced by these agents.
In addition, systemic administration of AC-263093 dose-dependently attenuated mechanical hypersensitivity following SNL, without altering the response thresholds of sham-operated rats, consistent with previous studies using microinjections in discrete brain stem regions (Xu et al., 1999; Altier et al., 2000; Wei et al., 2001) . In stark contrast to the effects observed with AC-263093, IP administration of the non-selective FF1/FF2 receptor agonist AC-262616 potentiated the severity of the SNL-induced hypersensitivity. Furthermore, IP administration of AC-262616 produced marked increases in sensitivity to both noxious thermal and to non-noxious mechanical stimuli in both naïve and sham-operated rats, respectively. Given that efficacy observed in the SNL model is correlated with the degree of FF2 functional selectivity, we hypothesized that the pronociceptive actions were a direct result of supraspinal FF1 receptor activation.
To date, the only well-characterized, and commercially-available, NPFF receptor antagonist is BIBP-3226 (Mollereau et al., 2002; Fang et al., 2006) . (Doods et al., 1995) . As a result, efficacy measured in vivo would be confounded as NPY1 antagonists effectively reverse SNL-induced mechanical hypersensitivity in their own right ).
Therefore we opted for dPQR, a putative NPFF receptor antagonist (Prokai et al., 2001) which crosses the blood-brain barrier (Prokai et al., 2000) , for our initial in vivo assessments. Systemic administration of dPQR reversed the pronociceptive actions of AC-262616, confirming biological activity of this FF1 receptor antagonist.
To determine whether endogenous NPFF systems play a role on the maintenance of mechanical hypersensitivity following SNL, we administered dPQR to neuropathic rats. Systemic administration of dPQR dose-dependently alleviated SNL-induced allodynia with a duration of action consistent with its published pharmacokinetic profile (Prokai et al., 2000) . These initial proof-of-concept data provided the impetus for the discovery of FF1 receptor antagonists. Like dPQR, both AC-262970 and AC-262620, two highly potent FF1 antagonists, with low nM affinity for FF1 receptors, attenuated SNL-induced mechanical hypersensitivity. It should be noted that these antagonists also elicited full agonist activity at FF2 receptors with potencies in the range of AC-263093.
Therefore, one possible interpretation is that the FF2 agonist activity of AC-262970 and AC-262620 is sufficient to attenuate SNL-induced hypersensitivity. However, this possibility is unlikely given that a) administration of AC-262616 produced mechanical and thermal hypersensitivity in naïve rats; b) dPQR is devoid of FF2 agonist activity; and c) AC-262620 is >150-fold selective in the functional R-SAT assay and is 20-fold 
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-28-selective for FF1 receptors in binding assays. Taken together, these data support the concept that, following peripheral nerve injury, FF1 receptor tone may be enhanced.
As previously mentioned, we are unaware of any reports confirming the presence of FF1 receptors in the spinal cord of rats, therefore, the pronociceptive actions of FF1 receptor activation would most likely originate in the brain. Since NPVF preferentially activates FF1 receptors, this endogenous peptide may be the source of pronociceptive drive, as in vitro studies have confirmed that it possesses anti-opioid activity (Liu et al., 2001; Kersante et al., 2006) . The ability of AC-262616 to significantly decrease baseline sensory thresholds suggests the possibility that FF1 receptor activation, in addition to promoting morphine antinociceptive tolerance, may also contribute to opioid-induced paradoxical pain. This idea is supported by the observation that intracerebroventricular administration of an anti-NPFF antiserum completely restores the efficacy of intracerebroventricular morphine in tolerant rats (Lake et al., 1991) . Additionally, administration of a pan FF1/FF2 receptor antagonist, RF9, prevents heroin-induced hyperalgesia and effectively blocks the development of antinociceptive tolerance following repeated heroin treatment (Simonin et al., 2006) .
Mechanistically, opioid-induced paradoxical pain and neuropathic pain share common features, including the activation of descending pain facilitatory pathways Burgess et al., 2002; . The activation of descending pain facilitation by anti-opioid peptides is not without precedence. For example, microinjection of cholecystokinin (CCK) into the rostralventromedial medulla produces mechanical hypersensitivity in naïve rats (Xie et al., 2005) , an effect similar to This article has not been copyedited and formatted. The final version may differ from this version. antagonists restore the antinociceptive potency of morphine in tolerant rats, reverse opioid-induced paradoxical pain (Xie et al., 2005) , and diminish mechanical allodynia in SNL rats (Kovelowski et al., 2000) . Given the similarities between the aforementioned effects with CCK and those reported herein with our FF1 receptor ligands, together with those reported elsewhere (Simonin et al., 2006) , highlights the possibility that supraspinal FF1 receptor activation may drive descending pain facilitatory pathways, although further work in this area is warranted.
In addition to the activation of descending pain facilitatory systems, opioidinduced paradoxical pain and neuropathic pain share another common feature which is the upregulation of spinal dynorphin Gardell et al., 2003) . While dynorphin is an endogenous kappa opioid receptor agonist, enhanced levels of this peptide promote neuropathic pain Burgess et al., 2002) , as well as opioid antinociceptive tolerance and opioid-induced paradoxical pain . Critically, manipulations which inhibit the pronociceptive actions of spinal dynorphin alleviate neuropathic pain Burgess et al., 2002; Gardell et al., 2003; Gardell et al., 2004) and reverses antinociceptive tolerance and the accompanying abnormal pain (Vanderah et al., 2000; . This is highly relevant as a recent study has shown that 1DMe suppresses spinal dynorphin release in anesthetized rats (Ballet et al., 2002) . Since FF1 receptors are not localized spinally the effects of 1DMe must therefore be driven by FF2 receptors, and thus represents a mechanism by which selective FF2 agonists may alleviate neuropathic pain and restore This article has not been copyedited and formatted. The final version may differ from this version. 
